At Nabla, we are building the next generation of antibody therapeutics through design, not discovery. Antibodies need to possess a multitude of properties to be manufacturable, safe, and efficacious for patients. Antibody engineering has a 99% failure rate today - it's too hard and inefficient to stumble onto these kinds of molecules using standard guess-and-check discovery techniques.
We're building a protein design platform that enables us to build antibodies deliberately, with all the properties they need to reach and treat patients, and do so faster than we can today.
Total Funding: N/A
Funding Stage: N/A
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2020
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Nabla Bio